• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    AirSculpt Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    6/11/25 4:15:43 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care
    Get the next $AIRS alert in real time by email
    false 0001870940 0001870940 2025-06-09 2025-06-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT 

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): June 9, 2025

     

    AirSculpt Technologies, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

    Delaware

    (State or Other Jurisdiction

    of Incorporation)

    001-40973

    (Commission

    File Number)

    87-1471855

    (IRS Employer

    Identification No.)

         
    1111 Lincoln Road, Suite 802
    Miami Beach, Florida
     

     

    33139

    (Address of Principal Executive Offices)   (Zip Code)

     

    (786) 709-9690

    (Registrant’s Telephone Number, Including Area Code)

     

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

     

    ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Each Class:   Trading
    Symbol(s):
     

    Name of Exchange
    on Which Registered:

    Common Stock, $0.001 par value per share   AIRS   The Nasdaq Global Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

     

     

     

     

     

    Item 1.01. Entry into a Material Definitive Agreement.

     

    On June 9, 2025, AirSculpt Technologies, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC (“Leerink Partners”), to issue and sell 3,160,000 shares (the “Firm Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”) to Leerink Partners, in an underwritten registered public offering (the “Offering”), at a price of $3.80 per share. Pursuant to the Underwriting Agreement, the Company also granted Leerink Partners a 30-day option to purchase up to an additional 474,000 shares of Common Stock (the “Additional Shares,” and together with the Firm Shares, the “Shares”), at the same price per share as the Firm Shares. Leerink Partners exercised in full its option to purchase the Additional Shares on June 10, 2025. Vesey Street Capital Partners, L.L.C., which is affiliated with two directors and is the largest stockholder of the Company, purchased an aggregate of 1,000,000 Shares in the Offering on the same terms and conditions as purchases by the public in the Offering.

     

    The Offering closed on June 11, 2025, and the Company received net proceeds of approximately $13.8 million from the sale of 3,634,000 Shares, which includes the 474,000 Additional Shares, after deducting estimated offering expenses. The Company currently intends to use a majority of the net proceeds from the Offering for the prepayment of a portion of the Company’s outstanding indebtedness under its existing credit agreement and the remainder of the net proceeds from the Offering for general corporate purposes, including working capital and other business opportunities.

     

    The Offering was pursuant to a prospectus supplement dated June 9, 2025, filed with the U.S. Securities and Exchange Commission (the “Commission”) in connection with the Company’s shelf registration statement on Form S-3 (File No. 333-285825), filed with the Commission on March 14, 2025 and declared effective on March 24, 2025 and the related prospectus dated March 14, 2025.

     

    The Underwriting Agreement contains customary representations, warranties, covenants, and agreements by the Company, customary conditions to closing and indemnification obligations of the Company and Leerink Partners (including for liabilities under the Securities Act of 1933, as amended), other obligations of the parties, and termination provisions. The representations, warranties, and covenants contained in the Underwriting Agreement were made only for purposes of the Underwriting Agreement and as of specific dates, were solely for the benefit of the parties thereto, and may be subject to limitations agreed upon by the contracting parties. In addition, subject to certain exceptions, the directors and officers and the largest stockholder of the Company have agreed not to offer, sell, transfer or otherwise dispose of any shares of Common Stock beneficially owned by them during the 90-day period following June 9, 2025.

     

    The description of the material terms of the Underwriting Agreement in this Item 1.01 does not purport to be complete and is qualified in its entirety by reference to the terms of the Underwriting Agreement, which is attached hereto as Exhibit 1.1 and is incorporated herein by reference. A copy of the legal opinion relating to the legality of the issuance and sale of the Shares in the Offering is attached hereto as Exhibit 5.1.

     

    Item 8.01. Other Events.

     

    On June 9, 2025, June 10, 2025 and June 11, 2025, the Company issued press releases relating to the Offering, which are attached hereto as Exhibits 99.1, 99.2 and 99.3, respectively, and are incorporated by reference herein.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit No.

     

    1.1 Underwriting Agreement by and between the Company and Leerink Partners LLC, dated June 9, 2025.
    5.1 Opinion of McDermott Will & Emery LLP dated June 11, 2025.
    23.1 Consent of McDermott Will & Emery LLP (included in the legal opinion filed as Exhibit 5.1 to this Current Report on Form 8-K).
    99.1 Press Release dated June 9, 2025.
    99.2 Press Release dated June 10, 2025.
    99.3 Press Release dated June 11, 2025.
    104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated: June 11, 2025  
       
      AirSculpt Technologies, Inc.
       
      By: /s/ Dennis Dean
        Name: Dennis Dean
        Title: Chief Financial Officer

     

    [Signature Page to the Form 8-K]

     

     

     

    Get the next $AIRS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIRS

    DatePrice TargetRatingAnalyst
    10/17/2024Neutral
    BTIG Research
    5/14/2024$8.25 → $5.00Outperform → Market Perform
    Leerink Partners
    11/11/2022$4.00Overweight → Neutral
    Piper Sandler
    6/16/2022$17.00 → $8.50Overweight → Equal-Weight
    Morgan Stanley
    11/23/2021$18.00Outperform
    Raymond James
    11/23/2021$17.00Overweight
    Morgan Stanley
    11/23/2021$26.00Outperform
    SVB Leerink
    11/23/2021$22.00Overweight
    Piper Sandler
    More analyst ratings

    $AIRS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Feinstein Adam T bought $4,000,000 worth of shares (1,000,000 units at $4.00) (SEC Form 4)

    4 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

    6/11/25 5:06:44 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    Executive Chairman Rollins Aaron bought $7,629 worth of shares (2,118 units at $3.60), increasing direct ownership by 0.01% to 15,146,039 units (SEC Form 4)

    4 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

    5/20/25 4:11:19 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    Chief Executive Officer Jashnani Yogesh bought $18,532 worth of shares (7,000 units at $2.65), increasing direct ownership by 2% to 464,879 units (SEC Form 4)

    4 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

    5/7/25 5:56:15 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    $AIRS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AirSculpt Technologies Announces Participation in Sidoti Micro Cap Conference

    MIAMI BEACH, Fla., Aug. 13, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS) ("AirSculpt" or the "Company"), a national provider of premium body contouring procedures, today announced that the Company will participate in the Sidoti Micro Cap Conference being held virtually from August 20 to 21, 2025. Management will meet with investors throughout both days and host a presentation at 10:00am ET on Wednesday, August 20. The presentation will be webcast live at https://investors.airsculpt.com. An archive of the webcast presentation will be available for 90 days. About AirSculpt AirSculpt is a next-generation body contouring treatment designed to optimize both comfort and

    8/13/25 6:00:00 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    AirSculpt Technologies Reports Second Quarter Fiscal 2025 Results

    MIAMI BEACH, Fla., Aug. 01, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS)("AirSculpt" or the "Company"), a national provider of premium body contouring procedures, today announced results for the second quarter ended June 30, 2025. The Company also announced that Dennis Dean intends to retire from his position of Chief Financial Officer. Mr. Dean will retain his role until a permanent successor is in place. Yogi Jashnani, Chief Executive Officer, stated: "In an ongoing dynamic environment, the second quarter saw us advance our transformation initiatives, and based on our results and our outlook, we remain on track to achieve our annual guidance. We narrowed our year-

    8/1/25 6:00:00 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    AirSculpt Technologies Announces Second Quarter Fiscal 2025 Earnings Release Date and Conference Call

    MIAMI BEACH, Fla., July 25, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. ("AirSculpt") (NASDAQ:AIRS), an industry leader and provider of premium body contouring procedures, today announced it will report second quarter 2025 financial results before market open on Friday, August 1, 2025, to be followed by a conference call on the same day at 8:30 a.m. Eastern Time. The conference call can be accessed by dialing 1-877-407-9716 (toll-free domestic) or 1-201-493-6779 (international) using the conference ID 13754561 or by clicking this link to request a return call for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Air

    7/25/25 6:45:00 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    $AIRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research initiated coverage on AirSculpt Technologies

    BTIG Research initiated coverage of AirSculpt Technologies with a rating of Neutral

    10/17/24 7:13:51 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    AirSculpt Technologies downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded AirSculpt Technologies from Outperform to Market Perform and set a new price target of $5.00 from $8.25 previously

    5/14/24 7:53:44 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    AirSculpt Technologies downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded AirSculpt Technologies from Overweight to Neutral and set a new price target of $4.00

    11/11/22 3:44:11 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    $AIRS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Feinstein Adam T bought $4,000,000 worth of shares (1,000,000 units at $4.00) (SEC Form 4)

    4 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

    6/11/25 5:06:44 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    Executive Chairman Rollins Aaron bought $7,629 worth of shares (2,118 units at $3.60), increasing direct ownership by 0.01% to 15,146,039 units (SEC Form 4)

    4 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

    5/20/25 4:11:19 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    Director Chu Caroline was granted 58,594 shares, increasing direct ownership by 50% to 176,780 units (SEC Form 4)

    4 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

    5/8/25 7:55:44 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    $AIRS
    SEC Filings

    View All

    SEC Form 10-Q filed by AirSculpt Technologies Inc.

    10-Q - Airsculpt Technologies, Inc. (0001870940) (Filer)

    8/1/25 3:43:27 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    AirSculpt Technologies Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Airsculpt Technologies, Inc. (0001870940) (Filer)

    8/1/25 3:38:52 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    AirSculpt Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

    8-K - Airsculpt Technologies, Inc. (0001870940) (Filer)

    8/1/25 6:06:52 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    $AIRS
    Financials

    Live finance-specific insights

    View All

    AirSculpt Technologies Announces Second Quarter Fiscal 2025 Earnings Release Date and Conference Call

    MIAMI BEACH, Fla., July 25, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. ("AirSculpt") (NASDAQ:AIRS), an industry leader and provider of premium body contouring procedures, today announced it will report second quarter 2025 financial results before market open on Friday, August 1, 2025, to be followed by a conference call on the same day at 8:30 a.m. Eastern Time. The conference call can be accessed by dialing 1-877-407-9716 (toll-free domestic) or 1-201-493-6779 (international) using the conference ID 13754561 or by clicking this link to request a return call for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Air

    7/25/25 6:45:00 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    AirSculpt Technologies Reports First Quarter Fiscal 2025 Results and Full Year Guidance

    MIAMI BEACH, Fla., May 02, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS)("AirSculpt" or the "Company"), a national provider of premium body contouring procedures, today announced results for the first quarter ended March 31, 2025. "We began the year reporting results in line with our expectations, and while we are early in our transformation, I am encouraged by the progress the team has made on the business imperatives we set in place at the start of the year and I remain confident that we have identified and are implementing the right actions to return to growth," stated Yogi Jashnani, Chief Executive Officer. "To this end, the first quarter saw profitability

    5/2/25 6:00:00 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    AirSculpt Technologies Announces First Quarter Fiscal 2025 Earnings Release Date and Conference Call

    MIAMI BEACH, Fla., April 25, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. ("AirSculpt") (NASDAQ:AIRS) an industry leader and provider of premium body contouring procedures, today announced it will report first quarter 2025 financial results before market open on Friday, May 2, 2025, to be followed by a conference call on the same day at 8:00 a.m. Eastern Time. The conference call can be accessed by dialing 1-877-407-9716 (toll-free domestic) or 1-201-493-6779 (international) using the conference ID 13753206 or by clicking this link to request a return call for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the AirScul

    4/25/25 6:45:00 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    $AIRS
    Leadership Updates

    Live Leadership Updates

    View All

    AirSculpt Technologies Names Yogi Jashnani Chief Executive Officer

    MIAMI BEACH, Fla., Dec. 17, 2024 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS) ("AirSculpt" or the "Company"), an industry leader and provider of premium body contouring procedures, today announced the appointment of Yogi Jashnani as Chief Executive Officer ("CEO") and a member of the Board of Directors. He succeeds Dennis Dean, Interim Chief Executive Officer and Chief Financial Officer who will continue as Chief Financial Officer, all effective January 7, 2025. A highly-talented, results oriented executive with an accomplished career spanning more than two decades, Mr. Jashnani has architected successful transformations for public and private companies in the aesthetics

    12/17/24 6:45:00 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    $AIRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by AirSculpt Technologies Inc.

    SC 13G/A - Airsculpt Technologies, Inc. (0001870940) (Subject)

    11/8/24 8:42:05 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    SEC Form SC 13G/A filed by AirSculpt Technologies Inc. (Amendment)

    SC 13G/A - Airsculpt Technologies, Inc. (0001870940) (Subject)

    2/14/24 1:11:48 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    SEC Form SC 13G filed by AirSculpt Technologies Inc.

    SC 13G - Airsculpt Technologies, Inc. (0001870940) (Subject)

    4/27/23 9:49:49 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care